Science & Enterprise subscription

Follow us on Twitter

  • A new enterprise, spun off from Seattle Children’s Research Institute, is creating therapeutics for diseases from e… https://t.co/CvnMEFT0Cm
    about 7 hours ago
  • New post on Science and Enterprise: Start-Up Developing Engineered B-Cell Therapies https://t.co/vMgdwnIXdi #Science #Business
    about 7 hours ago
  • Global drug maker Roche Group is acquiring an experimental antiviral therapy for Covid-19 infections taken as a ora… https://t.co/e2d7m6HG1E
    about 10 hours ago
  • New post on Science and Enterprise: Roche Gains Covid-19 Oral Drug Candidate https://t.co/nh27g6uCwi #Science #Business
    about 10 hours ago
  • The day that America lost $100 billion because of an immigration visa ban https://t.co/OfEx6SFwxA via @BrookingsInst
    about 23 hours ago

Please share Science & Enterprise

Start-Up Developing Engineered B-Cell Therapies

Human B-cell

A new enterprise, spun off from Seattle Children’s Research Institute, is creating therapeutics for diseases from engineered B-cells in the immune system. . . . → Read More: Start-Up Developing Engineered B-Cell Therapies

Carb-X Funding Nanoscale Sponge to Treat Sepsis

Hospital room

A company developing tiny particles made of cellular material to soak-up toxins in the body received a $4 million award to advance its sepsis treatment. . . . → Read More: Carb-X Funding Nanoscale Sponge to Treat Sepsis

Growing your Small Business Slowly is Super Important

Make sure that you don’t grow too quickly or you may end up stunting your own success. . . . → Read More: Growing your Small Business Slowly is Super Important

ALS Drug Shown to Extend Patient Survival

Motorized wheelchair

Results of a clinical trial show a drug to treat amyotrophic lateral sclerosis, or ALS, extends patients’ survival by several months and slows decline of their functions. . . . → Read More: ALS Drug Shown to Extend Patient Survival

Q3 Venture Funds Inch Up, Early-Stage Deals Drop

Early-stage venture Q3 2020

Venture capital funding rose in the third quarter of 2020, driven in large part by investments in already established companies rather than newer enterprises. . . . → Read More: Q3 Venture Funds Inch Up, Early-Stage Deals Drop

Cancer Center, Biotech Partner on Off-the-Shelf T-Cells

T-cells and cancer cells

MD Anderson Cancer Center and Allogene Therapeutics Inc. agreed to jointly study the company’s cancer treatments derived from donated T-cells. . . . → Read More: Cancer Center, Biotech Partner on Off-the-Shelf T-Cells

Gene Therapy Delivery Tech Licensed in $1.8B Deal

DNA puzzle

A biotechnology company creating synthetic viruses with artificial intelligence to deliver gene therapies is licensing its technology to drug maker Roche. . . . → Read More: Gene Therapy Delivery Tech Licensed in $1.8B Deal

Disaster-Proofing Your Business

Data breaches, compensation claims, and the competition are just three of the other issues that could hold disastrous repercussions for businesses. . . . → Read More: Disaster-Proofing Your Business

Individual Cells Explored with Virtual Reality

vLume image

A new software package uses virtual reality to allow biologists and medical researchers to visualize and explore inside individual cells in three dimensions. . . . → Read More: Individual Cells Explored with Virtual Reality

Start-Up Gains Access to Vaccine Nasal Spray Technology

Nasal spray

A company developing techniques to deliver vaccines like Covid-19 with a nasal spray received an opportunity to license the process from University of Houston. . . . → Read More: Start-Up Gains Access to Vaccine Nasal Spray Technology